Branislav Vajdic: The data component of our technology is very powerful, actually, because we have a set of parameters, ECG parameters describing that heart, patient’s heart that go well beyond the 12-Lead ECG. And applying AI to this data set, we strongly believe, will not only provide an increased value for reacting to an event, such as heart attack, but actually offering predictive and preventive value, which will be huge, we strongly believe. So, all in all, we are focusing right now on reacting to that heart attack system, right, doing the right thing for the patient, getting the right people to care or keep it running at home, basically saving lives and saving healthcare dollars. But we believe strongly that this data component of our data set will be hugely valuable going forward.
Operator: Our next question comes from the line of Ben Haynor with Alliance Global Partner.
Ben Haynor: First off, for me, Rob, nice to meet you over the conference call. But I was curious on what attracted you to HeartBeam and what are you most excited about going forward?
Robert Eno: Happy to talk about that. Just with my background, I have 28 years in medical technology, and it’s all based around bringing disruptive new technologies through commercialization and scale up. And I joined because I believe in the company and I believe in the technology and think this could be absolutely a chance to bring a game changing technology to market, being able to get a 12-Lead EKG into patients hands and with the VECG technology potentially being able to go beyond that, and the data aspects that Branislav mentioned. So I see it as a way to really influence a tremendous number of patients lives, address a major healthcare issue that has not yet been adequately addressed, and take part in what I think is going to be an amazing company going forward.
Ben Haynor: Have you had quite a few discussions with folks that could serve or could be potential customers down the road of AIMI, AIMIGo and the other products? Any color on those, if so?
Robert Eno: Sorry, can you repeat that? Just make sure I understand.
Ben Haynor: I was just curious, with your background, clearly, you probably a role that talking to folks that could be potential customers of AIMI, AIMIGo, the other products. Can you talk about any conversations that you’ve had and any color on those?
Robert Eno: Yeah, absolutely talk to a number of cardiologists. And what strikes me is €“ what I hear constantly is 12-Lead EKG itself is limited to hospitals, but it’s also a 100-year-old technology. And many of them know of the VECG process or the VCG process, vector cardiography. It was taught in medical schools years ago. It really never took off because physicians having to interpret 3D loops in space was very difficult. But they understand that studies, even decades ago, show that it had a number of benefits beyond standard EKG. So, we get a lot of excitement that the company has figured out a way to take ECG, harness it and bring it to patients. And then I hear a lot of physicians where we describe the concept of a full 12-Lead ECG or potentially beyond that in the hands of patients saying game changing, and they can think of all kinds of different applications for it.
So, I’ve been very pleased with the excitement of the physicians, the willingness to partner with us and help us, both in terms of potential clinical studies, early sites and helping us figure out the best strategies to scale the technology.
Ben Haynor: Sounds like support on your decision to join from folks that are trained about the technology. And then, on LIVMOR, congrats on the acquisition there. Are there any plans to commercialize the Halo+ AF detection system immediately? Or what’s kind of the commercialization thoughts there?
Branislav Vajdic: Yes, let me answer that question. We have acquired this system. And we have established that, actually, in terms of a potential product, what makes sense is an integration of Halo+ platform for AFib detection with our AIMIGo product. Why does that make sense? Well, as I said before, Halo+ is watch based. And it can provide a sort of an alert for AIMIGo to do a 12-Lead ECG where there are indications from the watch that there are things that are getting outside of the normal, right? And so, we believe that getting the AIMIGo to the FDA cleared state will enable us to consider offering an integrated product, where you have a watch that’s working with AIMIGo for a full-blown ability to detect a variety of conditions through our 12-Lead ECG.
And what’s interesting about that is that physicians under this scenario here would get something that was alerted by the watch, that they have learned is not very reliable, getting very many false positives, false negatives, et cetera. In this case, it will be validated by AIMIGo device. And that double validation, if you want, would probably mean that they believe in this referral from our system with a much higher degree of feasibility. So all in all, an integration makes sense. But AIMIGo is very much front and center of that system, potential integrated system. So we are still focused on AIMIGo totally and the potential integration into an integrated offering will translate.
Ben Haynor: That integration definitely makes sense. And then lastly for me, just given the optimism on the FDA timelines in your interactions with the agency, can you maybe characterize the questions that you’ve received? It doesn’t sound like there’s any showstoppers in there. But just any areas that common questions were arising or anything you could provide there would be helpful?
Branislav Vajdic: Well, I’m not at liberty to really talk about much detail there. I would just say that, at the top level, they are focused on cybersecurity, and rightfully so. So I think that’s as much as I can go into details, but all in all, again, productive interactions with the FDA.
Operator: And this concludes our dial in Q&A session. And we will now have questions via the webcast.
Unidentified Company Representative: Our first questioner asked, based on your IP, you can pursue several very interesting opportunities beyond AIMI and the initial AIMIGo planned releases. They would like to know what is the next product that you will start developing?
